Travatan prescribing information pdf




















Macular edema, including cystoid macular edema, has been reported during treatment with travoprost ophthalmic solution. TRAVATAN Z should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.

There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. In postmarketing use with prostaglandin analogs, periorbital and lid changes, including deepening of the eyelid sulcus have been observed.

There are no adequate and well-controlled studies in pregnant women to inform a drug-associated risk. In animal reproduction studies, subcutaneous SC administration of travoprost to pregnant mice and rats throughout the period of organogenesis produced embryo-fetal lethality, spontaneous abortion, and premature delivery at potentially clinically relevant doses. Advise pregnant women of a potential risk to a fetus. Because animal reproductive studies are not always predictive of human response, TRAVATAN Z should be administered during pregnancy only if the potential benefit justifies the potential risk to the fetus.

The background risk of major birth defects and miscarriage for the indicated population is unknown; however, in the U. An embryo-fetal study was conducted in pregnant rats administered travoprost once daily by SC injection from gestation day GD 6 to 18, to target the period of organogenesis.

An embryo-fetal study was conducted in pregnant mice administered travoprost once daily by SC injection from GD 6 to 11, to target the period of organogenesis. At doses of greater than or equal to 0. There are no data on the effects of travoprost on the breastfed child or milk production. It is not known if travoprost is present in human milk following ophthalmic administration. Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use.

No overall clinical differences in safety or effectiveness have been observed between elderly and other adult patients. Travoprost ophthalmic solution 0. No clinically relevant changes in hematology, blood chemistry, or urinalysis laboratory data were observed in these patients. Travoprost is a synthetic prostaglandin F analog. It has a molecular formula of C 26 H 35 F 3 O 6 and a molecular weight of The chemical structure of travoprost is:.

Travoprost is a clear, colorless to slightly yellow oil that is very soluble in acetonitrile, methanol, octanol, and chloroform. It is practically insoluble in water. Travoprost free acid, a prostaglandin analog is a selective FP prostanoid receptor agonist, which is believed to reduce IOP by increasing uveoscleral outflow. The exact mechanism of action is unknown at this time.

Heart Disease. Heart Rhythm. High Blood Pressure. Mental Health. Mental Health Issues. All Communities ». By subscribing, you agree to the Terms of Use and Privacy Policy. Travatan z prescribing information. Common Questions and Answers about Travatan z prescribing information.

I had surgery and a stent was placed in my right eye. I had an appointment with my eye doctor yesterday and he told me to stop taking the Travatan drops. I have noticed eyelash growth. I have discovered this is a side effect of the drops. Most of what I read says once the drops are discontinued, the eyelash growth is reversible.

What does that mean? How is it reversible? Read More. What you may be referring to is people with very very mild glaucoma and very little money that are on expensive drops like Lumigan and Travatan Z in some cases with very careful monitoring may be able to use the drops once every two or three days.

I think it not a good idea and don't do it in my practice. If there's a money problem I recommend selective laser trabeculoplasty. Suggest you call your ophthalmologist with this additional information.

I have not been cleared by my doctor to discontinue the nightly Travatan Z drop The surgeon turns his patients over to a optometrist in the practice for continued cataract care, so I haven't seen my doctor since the surgery.

In a few days, I have an appointment with a rheumatologist new patient and plan to request corticosteroid shots in two fingers and foot. Do you believe there would be a problem with me having the shots? Or any other rheumatoid arthritis meds? Thank you I use Travatan drops for the glaucoma so is there a difference Travatan Z? I do eye srubs every dayx2 with mild cetaphil soap since I have the inflammatory Rosacea on my face as well.

I need relief somehow. My eyes burn all the time. It has been so difficult the last few weeks. I really appreciate you help. Hopefully I spelled correctly. It hurts to look at his screen. Heart arrhythmia including PVCs is not likely due to Lumigan or the two other medications in that family Travatan- Z and latanoprost. Reduction of the IOP starts approximately 2 hours after the first administration with maximum effect reached after 12 hours. If more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

Travoprost ophthalmic solution has been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased pigmentation of the iris, periorbital tissue eyelid , and eyelashes.

Pigmentation is expected to increase as long as travoprost is administered. The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. After discontinuation of travoprost, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes have been reported to be reversible in some patients.

Patients who receive treatment should be informed of the possibility of increased pigmentation. The long-term effects of increased pigmentation are not known.

Iris color change may not be noticeable for several months to years. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish.

Neither nevi nor freckles of the iris appear to be affected by treatment. These changes include increased length, thickness, and number of lashes. Eyelash changes are usually reversible upon discontinuation of treatment. Macular edema, including cystoid macular edema, has been reported during treatment with travoprost ophthalmic solution. TRAVATAN Z should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.

There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. In postmarketing use with prostaglandin analogs, periorbital and lid changes including deepening of the eyelid sulcus have been observed.

There are no adequate and well-controlled studies in pregnant women to inform a drug-associated risk. In animal reproduction studies, subcutaneous SC administration of travoprost to pregnant mice and rats throughout the period of organogenesis produced embryo-fetal lethality, spontaneous abortion, and premature delivery at potentially clinically relevant doses. Advise pregnant women of a potential risk to a fetus. Because animal reproductive studies are not always predictive of human response, TRAVATAN Z should be administered during pregnancy only if the potential benefit justifies the potential risk to the fetus.



0コメント

  • 1000 / 1000